Introduction
============

Lung cancer is the most common cause of cancer death worldwide.[@b1-ott-9-1471] Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, and approximately two-thirds of NSCLC patients are diagnosed with advanced disease, which cannot be successfully treated by surgery.[@b2-ott-9-1471] Currently, platinum combined with a third-generation agent (docetaxel, paclitaxel, gemcitabine, vinorelbine, and pemetrexed) is the standard treatment option for advanced NSCLC.[@b3-ott-9-1471]--[@b6-ott-9-1471] However, NSCLC is a heterogeneous disease with respect to tumor histology, and those subtypes can be broadly categorized as squamous and nonsquamous. Recent clinical research related to histology has shown important differences within the population of patients with NSCLC.[@b7-ott-9-1471] In 2008, Scagliotti et al[@b8-ott-9-1471],[@b9-ott-9-1471] conducted a Phase III trial comparing first-line treatment using pemetrexed plus cisplatin with gemcitabine plus cisplatin and found that pemetrexed significantly improved overall survival (OS) in patients with nonsquamous histology (hazard ratio \[HR\] =0.81, 95% confidence interval \[CI\]: 0.70--0.94). However, in 2009, Gronberg et al[@b10-ott-9-1471] found that pemetrexed plus carboplatin provided similar OS when compared with gemcitabine plus carboplatin and that there was also no difference in OS when analyzing patients with nonsquamous histology (7.8 versus 7.5 months, *P*=0.77). As a result, whether pemetrexed plus platinum chemotherapy (PPC) is superior to other platinum-based doublet chemotherapy as first-line chemotherapy for advanced nonsquamous NSCLC patients remains unknown. To our best knowledge, there are no systematic review specially investigating the efficacy of PPC as first-line treatment for advanced nonsquamous NSCLC patients. We thus perform this study of published data to assess the efficacy of PPC in advanced nonsquamous NSCLC and compare the efficacy of PPC with other platinum-based doublet chemotherapy in those patients.

Materials and methods
=====================

Study design
------------

We developed a protocol that defined inclusion criteria, search strategy, outcomes of interest, and analysis plan. The reporting of this systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.[@b11-ott-9-1471]

Identification and selection of studies
---------------------------------------

To identify studies for inclusion in our systematic review and meta-analysis, we did a broad search of four databases, including Embase, Medline, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from the date of inception of every database to July 2015. The search included the following terms: "lung neoplasms", "lung carcinoma", "lung cancer", "pemetrexed", "first-line", "chemotherapy naive", "prospective study", and "clinical trials". Additional references were searched through manual searches of the reference lists and specialist journals. No language restrictions were applied.

To be eligible for inclusion in our systematic review and meta-analysis, study populations (referred to hereafter as cohorts) had to meet all the following criteria: 1) chemotherapy-naïve advanced nonsquamous NSCLC patients; 2) trials investigating the efficacy of PPC or comparing efficacy of PPC with other platinum-based doublet chemotherapy; 3) studies reporting outcomes of interest (ie, objective response rate \[ORR\], progression-free survival \[PFS\], and OS); and 4) reports from a prospective trial (ie, randomized controlled trial and nonrandomized clinical trial). If multiple publications of the same trial were retrieved or if there was a case mix between publications, only the most recent publication (and the most informative) was included.

Data extraction
---------------

Two investigators screened the titles and abstracts of potentially relevant studies. We retrieved the full text of relevant studies for further review by the same two reviewers. A third senior investigator resolved any discrepancies between reviewers. If reviewers suspected an overlap of cohorts in a report, they contacted the corresponding author for clarification; we excluded studies with a clear overlap.

The same pair of reviewers extracted study details independently, using a standardized pilot-tested form. A third investigator reviewed all data entries. We extracted the following data: author, study design, study period, median age, interventions (chemotherapy regimens and dose), sample size, and outcomes of interest. We defined outcomes of interest as ORR, PFS, and OS. The quality of reports of clinical trials was assessed and calculated using the 5-item Jadad scale including randomization, double-blinding, and withdrawals as previously described.[@b12-ott-9-1471]

Statistical analysis
--------------------

We prespecified the analysis plan in the protocol. We analyzed all patients who started PPC, regardless of their adherence to treatment. We calculated event rates of outcome (the proportion of patients who developed outcomes of interest) from the included cohorts for PPC groups. We pooled log-transformed event rates with DerSimonian and Laird random-effect models according to heterogeneity among studies.[@b13-ott-9-1471] We also pooled the overall HR for OS and PFS. A statistical test with a *P*-value \<0.05 was considered significant. To measure overall heterogeneity across the included cohorts, we calculated the *I*^2^ statistic, with *I*^2^\>50% indicating high heterogeneity. If heterogeneity existed, data were analyzed using a random-effects model. In the absence of heterogeneity, a fixed-effects model was used. We did all statistical analyses with comprehensive meta-analysis software version 2.0 (Biostat, Englewood, NJ, USA).

Results
=======

Search results
--------------

A total of 319 potentially relevant studies were retrieved electronically, 309 of which were excluded for the reasons shown in [Figure 1](#f1-ott-9-1471){ref-type="fig"}. Six cohorts from six trials[@b14-ott-9-1471]--[@b19-ott-9-1471] assessing the efficacy of PPC in patients with nonsquamous histology and four randomized controlled trials (RCTs)[@b8-ott-9-1471],[@b10-ott-9-1471],[@b20-ott-9-1471],[@b21-ott-9-1471] comparing PPC with other platinum-based doublet chemotherapy were included in the meta-analysis. The baseline characteristics of each trial are presented in [Table 1](#t1-ott-9-1471){ref-type="table"}. The quality of four RCTs was approximately assessed according to Jadad scale. Four of the included trials did not mention the blinding of allocation clearly in the randomization process and thus had Jadad scores of 3. Overall, a total of 1,565 patients with advanced nonsquamous NSCLC receiving PPC and 986 with other platinum-based doublet chemotherapy were included; the pooled median PFS and OS were 5.7 and 16.05 months, respectively. A total of 680 patients from seven trials receiving PPC as first-line chemotherapy were included for ORR analysis. The pooled overall response rate was 37.8% (95% CI: 31.7%--44.3%, [Figure 2](#f2-ott-9-1471){ref-type="fig"}). There was significant heterogeneity between the trials (*I*^2^=56.9%, *P*=0.031), and the pooled overall response was performed using a random-effects model. All of the four RCTs reported OS data. The pooled results demonstrated that PPC significantly improved OS in comparison with other platinum-based doublet chemotherapy treatments (0.86, 95% CI: 0.77--0.97, *P*=0.01, [Figure 3](#f3-ott-9-1471){ref-type="fig"}) using a fixed-effects model (*I*^2^=0%, *P*=0.65). Two of four RCTs reported PFS data. The pooled hazard ratio for PFS demonstrated that PPC tends to improve PFS by giving HR 0.90 (95% CI: 0.80--1.01, *P*=0.084, [Figure 4](#f4-ott-9-1471){ref-type="fig"}), compared with other platinum-based doublet chemotherapy in advanced nonsquamous NSCLC patients. There was no significant heterogeneity between trials (*I*^2^=0%, *P*=0.95), and the pooled HR for PFS was performed by using fixed-effects model.

Publication bias
----------------

Begg's funnel plot and Egger's test were performed to assess the publication bias of literatures. The Begg's funnel plots did not reveal any evidence of obvious asymmetry (*P*=0.50 for OS, [Figure 5](#f5-ott-9-1471){ref-type="fig"}). Then, Egger's test was used to provide statistical evidence of funnel plot symmetry. The results still did not suggest any evidence of publication bias for OS (*P*=0.05).

Discussion
==========

Many comprehensive and systematic reviews of the literature on PPC have been reported recently and are available for patients with advanced NSCLC.[@b3-ott-9-1471],[@b22-ott-9-1471]--[@b24-ott-9-1471] However, to the best of our knowledge, this study is the first meta-analysis specifically focusing on investigating the efficacy of PPC as first-line chemotherapy in advanced nonsquamous NSCLC patients. Our study includes a total of 1,565 patients with advanced nonsquamous NSCLC receiving PPC and 986 with other platinum-based doublet chemotherapy. The pooled results demonstrate that pooled ORR for PPC is 37.8% (95% CI: 31.7%--44.3%), with median PFS and OS of 5.7 and 16.05 months, respectively. In addition, the use of PPC significantly improves OS (HR =0.86, 95% CI: 0.77--0.97, *P*=0.01) but not PFS (HR =0.90, 95% CI: 0.80--1.01, *P*=0.084) in advanced nonsquamous NSCLC patients. Based on pooled results, we found that pemetrexed plus platinum doublet regimen is an efficacious treatment for advanced nonsquamous NSCLC patients when compared to other platinum-based doublet chemotherapies. However, the results of our meta-analysis regarding survival data are not solid because of the limited number of RCTs included for analysis. Further RCTs specifically comparing PPC with other platinum-based doublet chemotherapy as first-line chemotherapy in advanced nonsquamous NSCLC patients are still needed.

The pathogenesis of the higher treatment effect of PPC in nonsquamous NSCLC remains unknown. One possible mechanism to explain this effect could be that the expression of thymidylate synthase is higher in squamous NSCLC and lower in nonsquamous NSCLC, leading to lower sensitivity to pemetrexed in the squamous histotype and higher sensitivity in nonsquamous types.[@b25-ott-9-1471]

Our study has several limitations that need to be taken into account. First, all included studies were conducted at major academic institutions among patients with adequate major organ function; thus, the results may not entirely apply to the general patient population in the community or patients with organ dysfunction. Second, this is a meta-analysis at the study level; data are extracted from published clinical trial results, and individual patient information is not available. Therefore, subgroup analyses according to patients' characteristics are not possible in this analysis. Finally, in the meta-analysis of published studies, publication bias is important because trials with positive results are more likely to be published and trials with null results tend not to be published. Our research detects no publication bias for OS.

Conclusion
==========

In conclusion, pemetrexed plus platinum doublet regimen is an efficacious treatment for advanced nonsquamous NSCLC patients. Our findings support the use of pemetrexed plus platinum doublet regimens as first-line treatment in advanced nonsquamous NSCLC patients because of its potential survival benefits. Further investigation of this regimen as first-line treatment in nonsquamous NSCLC patients is still warranted.
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###### 

Baseline characteristics of ten trials included for meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                                     Country                      Chemotherapy regimen        Patients enrolled   Median age\   Median OS\   Median PFS\   ORR (%)
                                                                                                                          (years)       (months)     (months)      
  ------------------------------------------ ---------------------------- --------------------------- ------------------- ------------- ------------ ------------- ---------
  Scagliotti et al[@b8-ott-9-1471]           Multicenter                  Pemetrexed + cisplatin      618                 NR            11.8         5.3           NR

                                                                          Gemcitabine + cisplatin     614                 NR            10.4         4.7           NR

  Gronberg et al[@b10-ott-9-1471]            Multicenter                  Pemetrexed + carboplatin    162                 64            7.8          NR            NR

                                                                          Gemcitabine + carboplatin   167                 66            7.5          NR            NR

  Rodrigues-Pereira et al[@b20-ott-9-1471]   Multicenter                  Pemetrexed + carboplatin    106                 60.1          14.9         5.8           36

                                                                          Docetaxel + carboplatin     105                 58.9          14.7         6             NR

  Kim et al[@b14-ott-9-1471]                 Japan                        Pemetrexed + carboplatin    49                  63            24.3         7.9           51

  Kawano et al[@b15-ott-9-1471]              Japan                        Pemetrexed + cisplatin      50                  60            22.2         4.3           44.00

  Zhang et al[@b21-ott-9-1471]               People's Republic of China   Pemetrexed + platinum       105                 54            16.69        NR            NR

                                                                          Gemcitabine + platinum      100                 55            16.66        NR            NR

  Belani et al[@b16-ott-9-1471]              USA                          Pemetrexed + cisplatin      57                  59            15.9         7.1           26

  Kanazawa et al[@b17-ott-9-1471]            Japan                        Pemetrexed + carboplatin    41                  63            16.2         4.7           37

  Yu et al[@b18-ott-9-1471]                  People's Republic of China   Pemetrexed + platinum       59                  54.9          20.8         7             28

  Paz-Ares et al[@b19-ott-9-1471]            Multicenter                  Pemetrexed + cisplatin      318                 60            11.5         5.6           32.08
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** OS, overall survival; PFS, progression-free survival; ORR, objective response rate; NR, not reported.
